The buyer is not using this website to administer the notice.

To record your interest or obtain additional information or documents please find instructions within the Full Notice Text. (NOTE: Contract Award Notices and Prior Information Notices do not normally require a response)

Summary

OCID:
Published by:: The NHS Commissioning Board (operating under the name of NHS England)
Authority ID:: AA73994
Publication date:: 24 March 2020
Deadline date:: -
Notice type:: Contract Award Notice
Has documents:: No
Has SPD:: No
Has Carbon Reduction Plan:: N/A

Abstract

CM/PHR/16/5527/01 — 1.3.2020 to 28.2.2022 – NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.

Full notice text

Contract award notice

Results of the procurement procedure

Section I: Contracting entity

I.1) Name and addresses

The NHS Commissioning Board (operating under the name of NHS England)

2nd Floor, Rutland House,

Runcorn

WA7 2ES

E-mail: michelle.clarke6@nhs.net

NUTS: UK

Internet address(es)

Main address: https://nhsengland.bravosolution.co.uk

I.4) Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, Cytokine Modulators and Other Monoclonal Antibodies, and Fondaparinux

Reference number: CM/PHR/16/5527

II.1.2) Main CPV code

33600000

II.1.3) Type of contract

Supplies

II.1.4) Short description

NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, cytokine modulatorsand other monoclonal antibodies, and fondaparinux.

Offer reference number: CM/PHR/16/5527

CM/PHR/16/5527/01 — Tranche B: 1 March 2020 to 28 February 2022 with an option to extend (at the authority’s discretion)for a period or periods up to a total of 24 months.

CM/PHR/16/5527/02 – Annual tranche — cytokine modulators and other monoclonal antibodies — 1 March 2020 to 28 February 2021 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.

CM/PHR/16/5527/03 – NHS framework agreement for Fondaparinux — London – 1 March 2020 – 31 August 2021, Southof England – 1 March 2020 – 31 August 2020, Midlands and East – 1 March 2020 – 28 February 2021, all with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.

II.1.6) Information about lots

This contract is divided into lots: Yes

II.1.7) Total value of the procurement

Value excluding VAT: 514 043 196.00 GBP

II.2) Description

Lot No: 1

II.2.1) Title

NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKC

UKD

UKE

II.2.4) Description of the procurement

II.2.5) Award criteria

Quality criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents / Weighting: as above

Cost criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents / Weighting: as above

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 2

II.2.1) Title

NHS Framework for the NHS North of England Region, Branded Medicines – Annual Tranche — Cytokine Modulators and Other Monoclonal Antibodies

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKC

UKD

UKE

Main site or place of performance:

NHS Framework for the NHS North of England Region, Branded Medicines – Annual Tranche — Cytokine Modulators and other Monoclonal Antibodies.

II.2.4) Description of the procurement

CM/PHR/16/5527/02 – 1 March 2020 to 28 February 2021 — NHS Framework for the NHS North of England Region, branded medicines – annual tranche — cytokine modulators and other monoclonal antibodies with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.

II.2.5) Award criteria

Quality criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents / Weighting: as above

Cost criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents / Weighting: as above

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 3

II.2.1) Title

NHS Framework Agreement for Fondaparinux

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKC

UKD

UKE

UKF

UKG

UKH

UKI

UKJ

UKK

Main site or place of performance:

Please refer to document 3 schedule 8 in the ITO documents for a full list of purchasing points.

II.2.4) Description of the procurement

CM/PHR/16/5527/03 – NHS framework agreement for Fondaparinux — London – 1 March 2020 – 31 August 2021, with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.

South of England – 1 March 2020 – 31 August 2020, with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.

Midlands and East – 1 August 2020 – 28 February 2021, with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.

II.2.5) Award criteria

Quality criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents / Weighting: as above

Cost criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents / Weighting: as above

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

Notice number in the OJ S:

2019/S 193-468163

IV.2.9) Information about termination of call for competition in the form of a prior information notice

The contracting authority will not award any further contracts based on the above prior information notice

Section V: Award of contract

Lot No: 1

Contract No: CM/PHR/16/5527

Title: NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, Cytokine Modulatorsand other Monoclonal Antibodies, and Fondaparinux

A contract/lot is awarded: Yes

V.2 Award of contract

V.2.1) Date of conclusion of the contract

13/02/2020

V.2.2) Information about tenders

Number of tenders received: 37

Number of tenders received by electronic means: 37

The contract has been awarded to a group of economic operators: Yes

V.2.3) Name and address of the contractor

Acre Pharma Ltd

Unit 5-7 Tintagel Way

Aldridge

WS9 8ER

NUTS: UK

The contractor is an SME: Yes

V.2.3) Name and address of the contractor

Aspen Pharma Ireland Ltd

One George's Quay Plaza

Dublin

Dublin 2

NUTS: IE

The contractor is an SME: No

V.2.3) Name and address of the contractor

Astellas Pharma Ltd

SPACE, 68 Chertsey Road

Surrey

NUTS: UK

The contractor is an SME: No

Ferring Pharmaceuticals Ltd

Drayton Hall, Church Road, West Drayton

Greater London

NUTS: UK

The contractor is an SME: Yes

V.2.3) Name and address of the contractor

LEO Pharma

Horizon, Honey Lane

Berkshire

SL6 6RJ

NUTS: UK

The contractor is an SME: No

Total value of the contract/lot: : 514 043 196.00 GBP

V.2.5) Information about subcontracting

Section V: Award of contract

Lot No: 2

Contract No: CM/PHR/16/5527

Title: NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, Cytokine Modulatorsand other Monoclonal Antibodies, and Fondaparinux

A contract/lot is awarded: Yes

V.2 Award of contract

V.2.1) Date of conclusion of the contract

Berkshire

SL1 1QP

NUTS: UK

The contractor is an SME: No

V.2.4) Information on value of the contract/lot (excluding VAT)

Total value of the contract/lot: : 514 043 196.00 GBP

V.2.5) Information about subcontracting

Section V: Award of contract

Lot No: 3

Contract No: CM/PHR/16/5527

Title: NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, Cytokine Modulatorsand other Monoclonal Antibodies, and Fondaparinux

A contract/lot is awarded: Yes

V.2 Award of contract

V.2.1) Date of conclusion of the contract

13/02/2020

V.2.2) Information about tenders

Number of tenders received: 37

The contract has been awarded to a group of economic operators: Yes

V.2.3) Name and address of the contractor

Aspen Pharma Ireland Ltd

One George's Quay Plaza

Dublin

Dublin 2

NUTS: IE

The contractor is an SME: No

V.2.3) Name and address of the contractor

Dr Reddy's Laboratories Ltd

6 Rivervew Road

North Yorkshire

HU17 0LD

NUTS: UK

The contractor is an SME: Yes

V.2.4) Information on value of the contract/lot (excluding VAT)

Total value of the contract/lot: : 514 043 196.00 GBP

V.2.5) Information about subcontracting

Section VI: Complementary information

VI.3) Additional information

Awarded suppliers:

Acre Pharma Ltd

Amgen Ltd

Aspen Pharma Ireland Ltd

Astellas Pharma Ltd

Aventis Pharma Ltd T/A Sanofi

Bayer plc Pharmaceutical Division

Biogen Idec Ltd

Bristol-Myers Squibb Pharmaceuticals Ltd

Celltrion Healthcare UK Ltd

Daiichi Sankyo UK Ltd

DR Reddy's Laboratories

ELI Lilly and CO Ltd

Ferring Pharmaceuticals Ltd

Gedeon Richter UK Ltd

Mylan UK Healthcare

Gilead Sciences Ltd

Ipsen Ltd

Janssen-Cilag Ltd

LEO Pharmaceuticals

Merck Serono

Merck Sharp and Dohme Ltd

Napp Pharmaceuticals Group Ltd

Novartis Pharmaceuticals UK Ltd

Novo Nordisk Pharmaceuticals Ltd

Pfizer Ltd

Pharmasure Ltd

Profile Pharma

Roche Products Ltd

ROVI Biotech Ltd

Sandoz Ltd

Takeda UK Ltd

Techdow

TEVA UK Limited

Theramex HQ UK Ltd

Typharm Ltd

UCB Pharma Ltd

VI.4) Procedures for review

VI.4.1) Review body

The Royal Courts Of Justice

London or any of the district registry of the High Court

VI.5) Date of dispatch of this notice

20/03/2020

Coding

Commodity categories

ID	Title	Parent category
33600000	Pharmaceutical products	Medical equipments, pharmaceuticals and personal care products

Delivery locations

ID	Description
100	UK - All

Alert region restrictions

The buyer has restricted the alert for this notice to suppliers based in the following regions.

ID	Description
There are no alert restrictions for this notice.

About the buyer

Main contact:: michelle.clarke6@nhs.net
Admin contact:: N/a
Technical contact:: N/a
Other contact:: N/a

Further information

Date	Details
No further information has been uploaded.

NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, Cytokine Modulators and Other Monoclonal Antibodies, and Fondaparinux

Contents

Summary

Abstract

Full notice text

Contract award notice

Section I: Contracting entity

I.1) Name and addresses

I.4) Type of the contracting authority

I.5) Main activity

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

II.1.2) Main CPV code

II.1.3) Type of contract

II.1.4) Short description

II.1.6) Information about lots

II.1.7) Total value of the procurement

II.2) Description

II.2.1) Title

II.2.2) Additional CPV code(s)

II.2.3) Place of performance

II.2.4) Description of the procurement

II.2.5) Award criteria

II.2.11) Information about options

II.2.13) Information about European Union funds

II.2.1) Title

II.2.2) Additional CPV code(s)

II.2.3) Place of performance

II.2.4) Description of the procurement

II.2.5) Award criteria

II.2.11) Information about options

II.2.13) Information about European Union funds

II.2.1) Title

II.2.2) Additional CPV code(s)

II.2.3) Place of performance

II.2.4) Description of the procurement

II.2.5) Award criteria

II.2.11) Information about options

II.2.13) Information about European Union funds

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

IV.1.3) Information about a framework agreement or a dynamic purchasing system

IV.1.8) Information about Government Procurement Agreement (GPA)

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

IV.2.9) Information about termination of call for competition in the form of a prior information notice

Section V: Award of contract

V.2 Award of contract

V.2.1) Date of conclusion of the contract

V.2.2) Information about tenders

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.3) Name and address of the contractor

V.2.4) Information on value of the contract/lot (excluding VAT)